We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-18.32%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$875M
AUM Growth
-$123M
Cap. Flow
+$83.4M
Cap. Flow %
9.54%
Top 10 Hldgs %
28.77%
Holding
95
New
7
Increased
32
Reduced
30
Closed
6

Top Buys

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$14M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$11.4M
3
CNC icon
Centene
CNC
+$10.7M
4
BIIB icon
Biogen
BIIB
+$9.57M
5
UNH icon
UnitedHealth
UNH
+$9.35M

Top Sells

Rank Stock Value
1
AET
Aetna Inc
AET
+$10.1M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$8.4M
3
INCY icon
Incyte
INCY
+$7.17M
4
LOXO
Loxo Oncology, Inc
LOXO
+$6.07M
5
EXEL icon
Exelixis
EXEL
+$5.39M

Sector Composition

Rank Sector Weight
1 Healthcare 93.94%
2 Energy 0.12%
3 Technology 0.11%
4 Financials 0.09%
5 Communication Services 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CVX icon
76
Chevron
CVX
$366B
$406K 0.05%
3,733
– –
DIS icon
77
Walt Disney
DIS
$181B
$382K 0.04%
3,483
– –
ADVM
78
DELISTED
Adverum Biotechnologies
ADVM
$377K 0.04%
11,967
-3,430
-22% -$140K
QCOM icon
79
Qualcomm
QCOM
$176B
$369K 0.04%
6,476
– –
MSFT icon
80
Microsoft
MSFT
$3.71T
$293K 0.03%
2,887
– –
IBM icon
81
IBM
IBM
$224B
$280K 0.03%
2,574
– –
WFC icon
82
Wells Fargo
WFC
$264B
$270K 0.03%
5,858
– –
JPM icon
83
JPMorgan Chase
JPM
$950B
$268K 0.03%
2,747
-979
-26% -$104K
BUD icon
84
AB InBev
BUD
$165B
$249K 0.03%
3,788
– –
F icon
85
Ford
F
$55.7B
$248K 0.03%
32,405
– –
HAL icon
86
Halliburton
HAL
$26.6B
$245K 0.03%
9,221
– –
JHG
87
DELISTED
Janus Henderson
JHG
$245K 0.03%
11,828
– –
PFE icon
88
Pfizer
PFE
$153B
$219K 0.03%
5,279
-3,948
-43% -$164K
VIRX
89
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$157K 0.02%
10,778
-1,440
-12% -$58.8K
GEN icon
90
Gen Digital
GEN
$17.5B
– –
-9,734
Closed -$207K
GOOGL icon
91
Alphabet (Google) Class A
GOOGL
$4.33T
– –
-3,560
Closed -$215K
RGLS
92
DELISTED
Regulus Therapeutics
RGLS
– –
-4,107
Closed -$97K
PDCO
93
DELISTED
Patterson Companies, Inc.
PDCO
– –
-38,500
Closed -$941K
AET
94
DELISTED
Aetna Inc
AET
– –
-50,000
Closed -$10.1M
ZGNX
95
DELISTED
Zogenix, Inc.
ZGNX
– –
-60,000
Closed -$2.98M
1 2 3
4

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2018 Portfolio in Review

As of Q4 2018, Rhenman & Partners Asset Management held 95 positions worth $875M, down 12% from $998M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management deployed $83.4M of net new capital in Q4 2018, opening 7 new positions and adding to 32 existing holdings. Its largest new stake was bluebird bio: 9,098 shares worth $11.7M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 91% a quarter earlier, followed by Energy and Technology.

On the sell side, the largest reduction was BioMarin Pharmaceuticals, an estimated $8.4M trimmed.

  • Rhenman & Partners Asset Management's largest Q4 2018 buy was bluebird bio: 9,098 shares worth $11.7M.
  • Rhenman & Partners Asset Management added most to Neurocrine Biosciences in Q4 2018, an estimated $11.4M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2018 reduction was BioMarin Pharmaceuticals, cutting an estimated $8.4M.
  • Rhenman & Partners Asset Management fully exited Aetna Inc in Q4 2018, selling an estimated $10.1M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $875M portfolio in Q4 2018.
  • Rhenman & Partners Asset Management opened 7 new positions and closed 6 in Q4 2018.
  • Rhenman & Partners Asset Management's portfolio value fell 12% quarter-over-quarter to $875M.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2018, filed 5 Feb 2019.